Safety and value driving Phase IV growth at CROs; EVP

By Gareth Macdonald

- Last updated on GMT

Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

Jeff Trotter, executive vice president of Phase IV development at PharmaNet, told Outsourcing-Pharma that “the real world is real important​”. In recent years post-market safety has become increasingly important, boosting Phase IV business for contract research organisations (CRO).

This is now being accompanied by increased focus on value. Trotter said this spans other indications, cost-effectiveness and comparative effectives. More and more regulators will request post-approval data to prove a product has lived up to promise, said Trotter.

In April PharmaNet made three executive appointments to its Phase IV team.

Related news

Show more

Related products

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers